Abstract
BackgroundMaintainance of a stable basal insulin level is important for glycemic control in treatment of diabetes mellitus. Recently introduced insulin degludec has the longest duration of action among basal insulin formulations. The purpose of this study was to assess changes in quality of life (QOL) associated with switching the basal insulin regimen to degludec in patients with type 1 and type 2 diabetes mellitus.MethodsThis 24-week open-label intervention study included type 1 (n = 10) and type 2 (n = 20) diabetes mellitus patients, with adequately controlled hemoglobin A1c (HbA1c), who had received insulin glargine or detemir for at least 6 months. The primary outcome was change of QOL from baseline, as assessed by the Diabetes Therapy-Related QOL (DTR-QOL) application, after switching from glargine or detemir to degludec. HbA1c and other parameters were also assessed as secondary outcomes.ResultsQOL and HbA1c in patients with type 1 diabetes mellitus were unchanged during this study. In patients with type 2 diabetes mellitus, HbA1c did not change, but total DTR-QOL score was significantly improved from baseline after switching to degludec. The DTR-QOL Factor 2, “Anxiety and dissatisfaction with treatment”, was significantly improved in patients with type 2 diabetes mellitus and especially in the subgroup receiving basal supported oral therapy (BOT).ConclusionsSwitching of the basal insulin regimen from glargine or detemir to degludec significantly improved the QOL of patients with type 2 diabetes mellitus who were receiving BOT, by reducing mental stress or anxiety about their treatment.
Highlights
Maintainance of a stable basal insulin level is important for glycemic control in treatment of diabetes mellitus
We examined the change in quality of life (QOL) associated with a switch in basal insulin regimen from glargine or detemir to degludec in patients with type 1 and type 2 diabetes mellitus
The Diabetes Therapy-Related QOL (DTR-QOL) Factor 2 “Anxiety and dissatisfaction with treatment” subscale score was significantly improved in patients with type 2 diabetes mellitus at weeks 12 and 24 compared to baseline (Fig. 1 (b))
Summary
Maintainance of a stable basal insulin level is important for glycemic control in treatment of diabetes mellitus. The purpose of this study was to assess changes in quality of life (QOL) associated with switching the basal insulin regimen to degludec in patients with type 1 and type 2 diabetes mellitus. Insulin therapies often have adverse effects on quality of life (QOL). Most patients with type 1 diabetes mellitus receive intensive insulin therapy. For patients with type 2 diabetes mellitus, basal supported oral therapy (BOT), consisting of basal insulin injection and an oral. We examined the change in QOL associated with a switch in basal insulin regimen from glargine or detemir to degludec in patients with type 1 and type 2 diabetes mellitus
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have